Law Practice
Jun. 24, 2009
Biotech Sector Looks for Its Stimulus Cash
These are grim times for start-up biotech and life science companies. Yet, unlike the clean-tech industry, they aren't seeing a significant boost, at least not directly, from President Obama's $787 billion stimulus package.
By Pat Broderick
Daily Journal Staff Writer SAN DIEGO - These are grim times for start-up biotech and life science companies. Yet, unlike the clean-tech industry, they aren't seeing a significant boost, at least not directly, from President Obama's $787 billion stimulus package. According to figures supplied by Bio, an international association of biotech companies: Last year 16 percent of the 394 public U.S. biotechs that were active at the begin...
Daily Journal Staff Writer SAN DIEGO - These are grim times for start-up biotech and life science companies. Yet, unlike the clean-tech industry, they aren't seeing a significant boost, at least not directly, from President Obama's $787 billion stimulus package. According to figures supplied by Bio, an international association of biotech companies: Last year 16 percent of the 394 public U.S. biotechs that were active at the begin...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In